irbesartan/amlodipine

DRUG4 trials

Sponsors

Sanofi, Handok Inc.

Conditions

Essential HypertensionHypertension

Phase 2

Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

CompletedNCT04488978

Handok Inc.Essential Hypertension

Start: 2020-05-21End: 2021-11-09Updated: 2022-06-30

Phase 3

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy

CompletedNCT00956644

SanofiHypertension

Start: 2009-07-31End: 2010-08-31Target: 406Updated: 2010-10-26

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy

CompletedNCT00957554

SanofiHypertension

Start: 2009-07-31End: 2010-09-30Updated: 2010-10-26

Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients

CompletedNCT05475665

Handok Inc.Essential Hypertension

Start: 2022-07-14End: 2023-06-13Updated: 2023-08-18

Related Papers

The Efficacy and Tolerability of Irbesartan/Amlodipine Combination Therapy in Patients With Essential Hypertension Whose Blood Pressure Were not Controlled by Irbesartan Monotherapy.

2024-05-03

I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.

2012-07-3012 citations

I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.

2012-07-308 citations